MX2023002997A - Metodo de tratamiento de la amiloidosis. - Google Patents

Metodo de tratamiento de la amiloidosis.

Info

Publication number
MX2023002997A
MX2023002997A MX2023002997A MX2023002997A MX2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A
Authority
MX
Mexico
Prior art keywords
subject
treating
disorder
methods
amyloidosis disease
Prior art date
Application number
MX2023002997A
Other languages
English (en)
Spanish (es)
Inventor
Michael Spector
Susan B Sobolov-Jaynes
Michael Kahsai
Anthony S Lubiniecki
Jessica G Raviwong
Original Assignee
Caelum Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caelum Biosciences Inc filed Critical Caelum Biosciences Inc
Publication of MX2023002997A publication Critical patent/MX2023002997A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
MX2023002997A 2020-09-14 2021-09-14 Metodo de tratamiento de la amiloidosis. MX2023002997A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063078258P 2020-09-14 2020-09-14
US202063116100P 2020-11-19 2020-11-19
US202163176015P 2021-04-16 2021-04-16
PCT/US2021/050316 WO2022056484A1 (en) 2020-09-14 2021-09-14 Method of treating amyloidosis

Publications (1)

Publication Number Publication Date
MX2023002997A true MX2023002997A (es) 2023-05-11

Family

ID=80631942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002997A MX2023002997A (es) 2020-09-14 2021-09-14 Metodo de tratamiento de la amiloidosis.

Country Status (9)

Country Link
US (1) US20230364228A1 (https=)
EP (1) EP4210753A4 (https=)
JP (1) JP2023541191A (https=)
KR (1) KR20230069161A (https=)
AU (1) AU2021339851A1 (https=)
CA (1) CA3192069A1 (https=)
IL (1) IL301047A (https=)
MX (1) MX2023002997A (https=)
WO (1) WO2022056484A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240055101A (ko) * 2021-09-14 2024-04-26 시일럼 바이오사이언시즈, 인크. 다발성 골수종의 치료 방법
KR20250075597A (ko) * 2022-09-16 2025-05-28 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 심장 아밀로이드증의 치료를 위한 bag3 방법 및 용도
WO2025194030A1 (en) 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
US20090028847A1 (en) * 2007-04-12 2009-01-29 Trustees Of Boston University Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
EP4582446A3 (en) * 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis

Also Published As

Publication number Publication date
EP4210753A4 (en) 2025-01-08
AU2021339851A1 (en) 2023-04-13
US20230364228A1 (en) 2023-11-16
IL301047A (en) 2023-05-01
KR20230069161A (ko) 2023-05-18
EP4210753A1 (en) 2023-07-19
WO2022056484A1 (en) 2022-03-17
AU2021339851A8 (en) 2023-04-20
JP2023541191A (ja) 2023-09-28
CA3192069A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
MX2023002997A (es) Metodo de tratamiento de la amiloidosis.
JOP20230124A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
MY202279A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
MY199903A (en) Combination therapy with controlled-release cnp agonists
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
BR112023021131A2 (pt) Tratamento de tremor essencial
BR112022015151A2 (pt) Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
EP4484952A3 (en) Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
Novello et al. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2024004514A (es) Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo